论文信息 - Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial - 字舞流文

Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial

S. Kubicka | F. Lordick | N. Niederle | W. Freier | R. Porschen | D. Arnold | U. Keilholz | H. Schmoll | T. Hoehler | E. Kettner